Introduction {#s1}
============

Coronary heart disease (CHD) incurs a huge economic burden on healthcare and society ([@B14]). According to the epidemiological data from 1990 to 2013, 92.94 million people were suffering from this disease, which eventually led to 8.1 million deaths ([@B53]; [@B62]). Current treatments for CHD include coronary revascularization, drug intervention, risk factor control, cardiac rehabilitation, and lifestyle improvement ([@B1]). Among them, percutaneous coronary intervention (PCI) and coronary artery bypass grafting are the most effective ([@B60]). However, PCI is mainly for the treatment of locally severe stenotic vessels and has limited therapeutic effect on extensive coronary stenosis and microcirculation lesions ([@B22]). Meanwhile, the prognosis of patients treated with PCI is sometimes not ideal because myocardial ischemia/reperfusion injury, no reflow, coronary dissection, stent thrombosis, and acute coronary occlusion still exist ([@B19]; [@B1]). Although the technology of coronary intervention is still improving and conventional medicine is constantly updating, novel treatments that can stabilize arterial plaque, improve microcirculation, and angina symptoms; prevent acute myocardial infarction; delay the development of ischemic cardiomyopathy; ultimately reduce PCI; and improve prognosis are urgently needed.

Traditional Chinese medicine (TCM) includes herbal medicine (CHM), acupuncture, and other non-pharmacological therapies, which is a holistic approach to health and healing ([@B87]). CHM has been used to treat CHD for thousands of years, and in modern time, many claimed randomized controlled trials (RCT) have reported some TCM Fufang exerted the cardioprotective function ([@B18]; [@B17]; [@B11]; [@B38]). However, most of these studies are poor methodological quality, leading that there is still insufficient evidence to support routine use of CHMs for CHD. Thus, the Cochrane group guidelines for clinical reviews may exclude the ''not-so-good'' studies ([@B4]). In addition, in a TCM reviewing process, researchers may need to include such high-quality studies about a medical certain issue to identify current problems and areas worthy of improvement for its future development ([@B4]). Thus, we performed a systematic review to assess the efficacy and safety of CHM for CHD according to high-quality studies with at least four domains of "yes" in Cochrane risk of bias (RoB) tool ([@B32]).

Methods {#s2}
=======

Search Strategy and Study Selection {#s2_1}
-----------------------------------

Studies estimating the efficacy of CHMs in patients with CHD were systematically searched from EMBASE, PubMed, Cochrane Library, Wangfang database, China National Knowledge Infrastructure (CNKI), VIP database (VIP), and China Biology Medicine disc (CBM) from inception to the end of June 2018. The key words were used as follows: "coronary disease OR acute coronary syndrome OR myocardial infarction OR myocardial ischemia" AND "herb OR traditional Chinese medicine OR Chinese Materia Medica." Moreover, reference lists of potential articles were searched for relevant studies.

Inclusion and Exclusion Criteria {#s2_2}
--------------------------------

The inclusion criteria were prespecified as follows: (1) RCTs that investigated the efficacy and safety of CHM for CHD were included. Quasi-randomized trials, such as those in which patients were allocated according to date of birth and order of admission number, were excluded. If a three-arm design was used in a study, we extracted data only for the group(s) involving CHM and the control group(s). (2) All participants were patients with a diagnosis of CHD based on one of the following criteria: (1) The guideline of unstable or stable angina from Chinese cardiovascular association in different years, (2) the guideline of unstable or stable angina from American College of Cardiology (ACC) or American Heart Association (AHA) or European Society of Cardiology (ESC) or World Health Organization (WHO) in different years, (3) be diagnosed by coronary angiography, (4) patients after PCI, and (5) diagnostic criteria made by other authors with comparable definitions were also used. (3) The treatment interventions included CHMs used as monotherapies or adjunct with conventional medicine (i.e., antiplatelet, stable plaque, control ventricular rate) or supportive treatment (i.e., nutrition support, exercise therapy, psychotherapy). Interventions for control group were restricted to no intervention, placebo, conventional medicine, and supportive treatment. Studies comparing a CHM agent with another CHM agent were excluded. (4) The primary outcome measures were the incidence of myocardial infarction and/or the incidence of PCI and/or cardiovascular mortality and/or the level of ST-segment depression and/or indicators which represent systolic and diastolic function of the heart in cardiac ultrasound. The secondary outcome measures were clinical effective rating, and the safety of co-administration of CHM. The exclusion criteria were prespecified as follows: (1) no predetermined outcome index; (2) compared or combined with other Chinese herb medicine; (3) not randomized, double-blind, placebo-controlled designed; (4) no control group; and (5) double publication.

Data Extraction {#s2_3}
---------------

Two authors independently reviewed each included study and extracted following aspects of details: (1) name of first author, year of publication; (2) diagnostic criteria; (3) detail information of participants for each study, including sample size, gender composition, and mean age; (4) detail information of treatment and control group, including therapeutic drug dosage, method of administration, and duration of treatment; and (5) outcome measures and intergroup differences. The data of predetermined primary and secondary outcomes were extracted for further qualitative and quantitative syntheses. We made efforts to contact authors for further information when some records' published data were only in graphical format or not in the publication. And the numerical values were measured from the graphs by digital ruler software when response was not received from authors.

Risk of Bias in Individual Studies {#s2_4}
----------------------------------

The methodological quality of each included study was evaluated by two authors with the seven-item checklist recommended by Cochrane Collaboration ([@B24]). Only RCTs with a cumulative score of at least four points were included in our systematic review. Any disagreements from two authors were dealt with through discussion with the corresponding author (GQZ).

Statistical Analysis {#s2_5}
--------------------

The statistical analysis was conducted *via* RevMan version 5.3. A fixed-effects model (FEM) or random-effects model (REM) was conducted to analyze pooled effects. When the outcome measurements in all included studies in meta-analysis were based on the same scale, weighted mean difference (WMD) with 95% confidence intervals was calculated as a summary statistic, otherwise standard mean difference (SMD) was calculated. Heterogeneity between study results was investigated based on a standard chi-square test and I^2^ statistic. A fixed-effects model (I^2^ \< 50%) or a random-effects model (I^2^ \> 50%) was used depending on the value of I^2^. Funnel plots were used to visually estimate publication bias. A probability value 0.05 was considered statistically significant.

CHM Composition and Possible Mechanisms of Active Ingredients {#s2_6}
-------------------------------------------------------------

Specific herbs in the CHM formulae were recorded. The frequency of use for particular herb was calculated and those used at a high frequency that are described in detail. Animal-based mechanism studies of active ingredients from frequently used herbs were searched. The following information was recorded for such studies: identity of active ingredients and their herbal sources, suggested mechanisms and implicated signaling pathways, first author's name and publication year of the citation, and structure of active ingredients.

Results {#s3}
=======

Study Selection {#s3_1}
---------------

A total of 2,158 studies were retrieved after systematical searches from the database, of which 287 were reduplicated and irrelevant studies. After screening title and abstract, 180 were excluded because they were: (1) animal trial, (2) case report, (3) review article, and (4) meeting abstract. After reviewing the full text of the remaining 87 articles, 60 studies were excluded if: (1) no predetermined outcome index; (2) compared or combined with other CHM; (3) not randomized, double-blind, and placebo-controlled designed; (4) no control group; (5) double publication; and (6) data of result was not available. Ultimately, 27 studies with Cochrane RoB score ≧4 ([@B45]; [@B58]; [@B46]; [@B9]; [@B10]; [@B59]; [@B72]; [@B96]; [@B66]; [@B52]; [@B76]; [@B77]; [@B5]; [@B65]; [@B25]; [@B36]; [@B43]; [@B67]; [@B85]; [@B86]; [@B100]; [@B13]; [@B49]; [@B75]; [@B102]; [@B74]; [@B89]) were selected ([**Figure 1**](#f1){ref-type="fig"}).

![Summary of the process for identifying candidate studies.](fphar-10-00844-g001){#f1}

Characteristics of Included Studies {#s3_2}
-----------------------------------

17 studies ([@B45]; [@B58]; [@B9]; [@B10]; [@B59]; [@B52]; [@B76]; [@B77]; [@B5]; [@B25]; [@B36]; [@B43]; [@B67]; [@B85]; [@B86]; [@B13]; [@B102]; [@B74]; [@B89]) were published in Chinese and 10 studies ([@B46]; [@B72]; [@B96]; [@B10]; [@B66]; [@B65]; [@B86]; [@B100]; [@B49]; [@B75]) in English between 2006 and 2017. All studies were conducted in China. The sample size of the included studies ranged from 57 to 4,870 with a total of 11,732 participants, including 5,916 patients in treatment groups and 5,816 patients serving as controls. Of 27 included studies, 18 studies ([@B9]; [@B59]; [@B72]; [@B66]; [@B52]; [@B76]; [@B65]; [@B25]; [@B36]; [@B67]; [@B85]; [@B100]; [@B13]; [@B75]; [@B102]; [@B74]; [@B89]) were based on patients with angina pectoris of CHD and nine studies ([@B45]; [@B58]; [@B46]; [@B10]; [@B96]; [@B5]; [@B43]; [@B86]; [@B49]) were based on patients with acute coronary syndrome. Comparisons of CHM plus a conventional treatment (i.e., antiplatelet, stable plaque, control ventricular rate) *versus* a conventional treatment were conducted in 26 trials, and comparisons of CHM versus a placebo were performed in one trial ([@B25]). The CHMs were administered orally (i.e., tablets, capsules, granules, or decoction). The duration of follow-up was varied from 4 weeks to 4.5 years. All studies accounted for baseline comparability. The incidence of myocardial infarction (MI) was utilized as outcome measure in 10 studies ([@B45]; [@B46]; [@B72]; [@B66]; [@B65]; [@B43]; [@B67]; [@B86]; [@B49]; [@B75]), the incidence of PCI in five studies ([@B45]; [@B46]; [@B72]; [@B65]; [@B75]), cardiovascular mortality in seven studies ([@B46]; [@B72]; [@B65]; [@B67]; [@B86]; [@B49]; [@B75]), left ventricular ejection fraction (LVEF) in five studies ([@B58]; [@B59]; [@B5]; [@B67]; [@B49]), the ventricular wall motion score in two studies ([@B58]; [@B5]), and the level of ST-segment elevation in three studies ([@B10]; [@B25]; [@B67]). The efficiency of angina improved was reported in 12 studies ([@B45]; [@B10]; [@B66]; [@B52]; [@B76]; [@B25]; [@B43]; [@B67]; [@B100]; [@B13]; [@B102]; [@B89]), the usage of nitroglycerin in two studies ([@B67]; [@B85]), low-density lipoprotein (LDL) in four studies ([@B46]; [@B77]; [@B102]; [@B74]), hypersensitive C-reactive protein (hsCRP) in two studies ([@B52]; [@B76]), the degree of coronary artery stenosis in two studies ([@B45]; [@B89]), and the rate of coronary restenosis in two studies ([@B66]; [@B43]). The overall characteristics of included studies are shown in [**Table 1**](#T1){ref-type="table"}.

###### 

Characteristics of the 27 included studies.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study (years)   Diagnostic criteria                                                                Number of participants (male/female), mean age (years)   Interventions        Conventional medicine or basic treatment                              Duration of treatment   Outcome index                                                                                                                  Intergroup differences                                                                      
  --------------- ---------------------------------------------------------------------------------- -------------------------------------------------------- -------------------- --------------------------------------------------------------------- ----------------------- ------------------------------------------------------------------------------------------------------------------------------ ------------------------ ------------------------------------------------------------------ -----------------
  [@B45]          After PCI                                                                          60\                                                      58\                  Xiongshao capsule (0.5g, tid, p.o).                                   Placebo                 Clopidogrel, aspirin; atorvastatin, low molecular weight heparin                                                               6 months                 1\. Cardiovascular mortality\                                      1\. P \< 0.05\
                                                                                                     58.94 ± 10.79                                            57.1 ± 9.81                                                                                                                                                                                                                                                                2. The rate of coronary restenosis\                                2. P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         3. The degree of coronary artery stenosis\                         3. P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         4. The efficiency of angina pectoris\                              4. P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         5. Myocardial infarction rate\                                     5. P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         6. The incidence of PCI                                            6. P \< 0.05

  [@B58]          After PCI                                                                          30 (17/13)\                                              29 (18/11)\          Tongguan capsule (three doses, tid, p.o).                             Placebo                 Anticoagulant, antiplatelet, anti-infection                                                                                    1 month                  1\. LVEF\                                                          1\. P \< 0.05\
                                                                                                     64.0 ± 11.2                                              65.7 ± 12.2                                                                                                                                                                                                                                                                2. The ventricular wall motion score\                              2. P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         3. Survey of angina pectoris in Seattle                            3. P \< 0.05

  [@B46]          Documented previous myocardial infarction                                          2,429\                                                   2,441\               Xuezhikang capsule (0.6g, bid, p.o).                                  Placebo                 Other drugs that do not affect blood lipids                                                                                    4.5 years                1\. Myocardial infarction rate\                                    1\. P \< 0.05\
                                                                                                     58.35 ± 9.02                                             58.35 ± 9.02                                                                                                                                                                                                                                                               2. Cardiovascular mortality\                                       2. P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         3. The incidence of PCI\                                           3. P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         4. TC\                                                             4. P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                         5. TG\                                                             5. P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                         6. HDL-C\                                                          6. P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                         7. LDL-C                                                           7. P \< 0.01

  [@B9]           The guideline of chronic stable angina from China, 2007                            41 (37/4)\                                               41 (39/2)\           Qingre Quyu granule (6g, bid, p.o).                                   Placebo                 Aspirin, bisoprolol fumarate, isosorbide dinitrate sustained release tablets                                                   25 weeks                 1\. Number of atherosclerotic plaques\                             1\. P \< 0.05\
                                                                                                     49.97 ± 6.19                                             51.12 ± 7.33                                                                                                                                                                                                                                                               2. Arterial plaque score\                                          2. P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         3. Intima thickness of carotid artery\                             3. P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         4. hsCRP                                                           4. P \< 0.05

  [@B59]          The guideline of acute myocardial infarction from China, 2001                      51 (45/6)\                                               52 (44/8)\           Compound *Salvia* tablet and Xinyue capsule                           Placebo                 Antiplatelet agents, anticoagulant, β blocker, angiotensin converting enzyme inhibitor, nitrates, and lipid-regulating drugs   3 months                 1\. LVEF                                                           1\. P \< 0.05
                                                                                                     57.82 ± 10.23                                            55.79 ± 11.06                                                                                                                                                                                                                                                                                                                                 

  [@B72]          The guideline of unstable angina pectoris from ACC/AHA USA, 2002                   32 (12/20)\                                              31 (13/18)\          Shenshao tablet (0.3g, qd, p.o).                                      Placebo                 Aspirin, isosorbide, mononitrate, simvastatin, Benner Pury, amlodipine,\                                                       4 weeks                  1\. Frequency of angina pectoris\                                  1\. P \< 0.05\
                                                                                                     61.65 ± 8.15                                             64.47 ± 9.21                                                                                                       metoprolol                                                                                                                                              2. Seattle score\                                                  2. P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         3. The incidence of PCI\                                           3. P \> 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         4. Acute myocardial infarction rate                                4. P \> 0.05

  [@B10]          After PCI                                                                          28 (18/10);\                                             29 (20/9);\          Xuefu Zhuyu capsule                                                   Placebo                 Clopidogrel, aspirin, low molecular weight heparin, metoprolol tartrate, atorvastatin                                          4 weeks                  1\. The efficiency of angina pectoris\                             1\. P \< 0.05\
                                                                                                     61.7 ± 9.6                                               58.8 ± 8.9                                                                                                                                                                                                                                                                 2. Electrocardiogram curative effect\                              2. P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         3. Survey of angina pectoris in Seattle                            3. P \< 0.05

  [@B96]          The guideline of segment elevation myocardial infarction from WHO                  108 (92/16)\                                             111 (96/15)\         Tongxinluo (2.08g, qd, p.o).                                          Placebo                 Aspirin, clopidogrel                                                                                                           180 days                 1\. The incidence of no reflow of myocardium                       1\. P = 0.0031
                                                                                                     58.5 ± 10.6                                              57.6 ± 11.2                                                                                                                                                                                                                                                                                                                                   

  [@B66]          The guideline of stable angina pectoris from WHO                                   73 (50/23)\                                              79 (52/27)\          Chuangxiongol (250mg, tid, p.o).                                      Placebo                 Aspirin, tilopidine, diltiazem, nitroglycerin, heparin                                                                         6 months                 1\. Restenosis rate\                                               1\. P \> 0.05\
                                                                                                     67.79 ± 4.77                                             66.7 ± 4.16                                                                                                                                                                                                                                                                2. The efficiency of angina pectoris\                              2. P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                         3. Cardiovascular mortality\                                       3. P \> 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         4. Acute myocardial infarction rate\                               4. P \> 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         5. The incidence of PCI                                            5. P \> 0.05

  [@B52]          The guideline of criteria for the naming and diagnosis of ischemic heart disease   60 (43/17)\                                              60 (42/18)\          Yixin Mai granule (one dose, tid, p.o).                               Placebo                 Isosorbide, metoprolol, fosinopril, aspirin                                                                                    4 weeks                  1\. hsCRP\                                                         1\. P \< 0.01\
                                                                                                     67.15 ± 4.87                                             66.22 ± 5.12                                                                                                                                                                                                                                                               2. IL-6\                                                           2. P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                         3. IL-18\                                                          3. P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                         4. The efficiency of angina pectoris                               4. P = 0.037

  [@B76]          The guideline of unstable angina pectoris from ACC/AHA USA, 2002                   33 (26/7)\                                               33 (25/8)\           Tablets of betel (1.5g, bid, p.o).                                    Placebo                 Aspirin, simvastatin, isosorbide, dinitrate                                                                                    28 days                  1\. The efficiency of angina pectoris\                             1\. P \< 0.05\
                                                                                                     60.2 ± 9                                                 62.7 ± 7.1                                                                                                                                                                                                                                                                 2. Electrocardiogram efficiency\                                   2. P \> 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         3. Nitroglycerin consumption\                                      3. P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         4. hsCRP\                                                          4. P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         5. sCD40L                                                          5. P \< 0.05

  [@B77]          The guideline of chronic stable angina from China, 2007                            76                                                       72                   Double ginseng capsule and Tongguan capsule (four doses, tid, p.o).   Placebo                 Original treatment                                                                                                             6 months                 1\. TG\                                                            1\. P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         2. TC\                                                             2. P \> 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         3. HDL-C\                                                          3. P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         4. LDL-C                                                           4. P \< 0.05

  [@B5]           After PCI                                                                          30 (17/13)\                                              30 (16/14)\          Tongguan capsule (three doses, tid, p.o).                             Placebo                 Clopidogrel, aspirin, low molecular weight heparin                                                                             3 months                 1\. LVEF\                                                          1\. P \< 0.05\
                                                                                                     65.5 ± 7.5                                               63.8 ± 6.3                                                                                                                                                                                                                                                                 2. The ventricular wall motion score\                              2. P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         3. The number of endothelial progenitor cell in peripheral blood   3. P \< 0.05

  [@B65]          The guideline of chronic stable angina from China, 2004                            1,746 (1,191/555)\                                       1,759 (1,260/499)\   QSYQ (0.5g, tid, p.o).                                                Placebo                 Antihypertensive drugs, hypoglycemic agent, lipid-lowering medicine                                                            12 months                1\. Cardiovascular mortality\                                      1\. P \> 0.05\
                                                                                                     58.35 ± 9.02                                             58.28 ± 8.99                                                                                                                                                                                                                                                               2. Myocardial infarction rate\                                     2. P \> 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         3. The incidence of PCI                                            3. P \> 0.05

  [@B25]          The guideline of chronic stable angina from China, 2007                            192\                                                     99\                  Reachable film (three doses, tid, p.o).                               Placebo                 NM                                                                                                                             4 weeks                  1\. The efficiency of angina pectoris\                             1\. P \< 0.05\
                                                                                                     57.82 ± 10.23                                            57.82 ± 10.23                                                                                                                                                                                                                                                              2. The total curative effect of TCM Syndrome\                      2. P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         3. Electrocardiogram efficiency                                    3. P \< 0.05

  [@B36]          The guideline of chronic stable angina from China, 2007                            120\                                                     120\                 Chek Shincen Tongxin granule                                          Placebo                 Aspirin, atorvastatin                                                                                                          4 weeks                  1\. Body limitation\                                               1\. P \< 0.05\
                                                                                                     59.21 ± 7.92                                             60.64 ± 7. 69                                                                                                                                                                                                                                                              2. Stable state of angina pectoris\                                2. P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         3. Episodes of angina pectoris\                                    3. P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         4. Satisfaction with treatment\                                    4. P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         5. The degree of understanding of disease\                         5. P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         6. Electrocardiogram efficiency                                    6. P \< 0.05

  [@B43]          After PCI                                                                          90 (48/42)\                                              90 (46/44)\          Tongxinluo capsule (three doses, tid, p.o).                           Placebo                 Original treatment                                                                                                             12 months                1\. The incidence of coronary restenosis\                          1\. P \< 0.05\
                                                                                                     60.2 ± 6.9                                               61.8 ± 7.2                                                                                                                                                                                                                                                                 2. The degree of coronary restenosis\                              2. P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                         3. The efficiency of angina pectoris\                              3. P = 0.04\
                                                                                                                                                                                                                                                                                                                                                                                                                                         4. Myocardial infarction rate\                                     4. P = 0.19\
                                                                                                                                                                                                                                                                                                                                                                                                                                         5. Cardiovascular mortality                                        5. P \> 0.05

  [@B67]          The guideline of chronic unstable angina from China, 2007                          64 (42/22)\                                              64 (44/20)\          Musk Baoxin pill (two doses, tid, p.o).                               Placebo                 Isosorbide dinitrate tablets, atorvastatin, thiazepine, enteric aspirin                                                        6 months                 1\. The efficiency of angina pectoris\                             1\. P \< 0.05\
                                                                                                     70.81 ± 10.76                                            69.8 ± 10.98                                                                                                                                                                                                                                                               2. Myocardial infarction rate\                                     2. P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         3. Cardiovascular mortality\                                       3. P \> 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         4. Nitroglycerin consumption\                                      4. P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                         5. Electrocardiogram efficiency\                                   5. P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         6. LVEF                                                            6. P \< 0.05

  [@B85]          The guideline of unstable angina pectoris from ACC/AHA USA, 2002                   55 (29/26)\                                              59 (33/26)\          Shenzhu Guanxin recipe (12g, qd, p.o).                                Placebo                 Conventional western medicine (unspecified)                                                                                    12 weeks                 1\. The efficiency of angina pectoris\                             1\. P \< 0.05\
                                                                                                     69.47 ± 8                                                70.41 ± 8.6                                                                                                                                                                                                                                                                2. The duration of angina pectoris\                                2. P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         3. Total use of nitroglycerin\                                     3. P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         4. The degree of physical activity induced by angina pectoris\     4. P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         5. The degree of angina pectoris                                   5. P \< 0.01

  [@B86]          After PCI                                                                          113 (86/27)\                                             74 (51/23)\          Shenzhu Guanxin recipe                                                Placebo                 Aspirin, ticplopidine, diltiazem, glyceryl, trinitrate, heparin                                                                3 months                 1\. Angina pectoris score\                                         1\. P = 0.66\
                                                                                                     70.35 ± 9.61                                             68.08 ± 10.38                                                                                                                                                                                                                                                              2. Cardiovascular mortality\                                       2. P = 0.33\
                                                                                                                                                                                                                                                                                                                                                                                                                                         3. Myocardial ischemia rate                                        3. P = 0.63

  [@B100]         The guideline of unstable angina pectoris from ACC/AHA USA, 2002                   119 (56/63)\                                             120 (52/68)\         Wufuxinnaoqing capsules                                               Placebo                 Antiplatelet, aggregation, ACEI or ARB, statin two hydrogen arsenide                                                           12 weeks                 1\. The efficiency of angina pectoris\                             1\. P \< 0.01\
                                                                                                     59.46 ± 6.524                                            58.82 ± 7.061                                                                                                                                                                                                                                                              2. Nitroglycerin consumption                                       2. P \< 0.01

  [@B13]          The guideline of chronic stable angina from China, 2007                            64 (38/26)\                                              67 (47/20)\          Live heart pill (two doses, tid, p.o).                                Placebo                 Conventional western medicine (unspecified)                                                                                    8 weeks                  1\. Symptom score of angina pectoris\                              1\. P \< 0.01\
                                                                                                     59.7 ± 6.34                                              60.7 ± 6.44                                                                                                                                                                                                                                                                2. Nitroglycerin consumption\                                      2. P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                         3. Electrocardiogram plate movement\                               3. P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                         4. Seattle scale\                                                  4. P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                         5. Syndromes of traditional Chinese Medicine\                      5. P \< 0.01\
                                                                                                                                                                                                                                                                                                                                                                                                                                         6. hsCRP\                                                          6. P \> 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         7. Blood lipid                                                     7. P \> 0.05

  [@B49]          After PCI                                                                          42\                                                      41\                  Danlou tablet                                                         Placebo                 Conventional western medicine (unspecified)                                                                                    90 days                  1\. Left ventricular end diastolic volume index\                   1\. P \< 0.001\
                                                                                                     67.54 ± 8.39                                             68.38 ± 10.41                                                                                                                                                                                                                                                              2. End systolic volume index of left ventricle\                    2. P \< 0.001\
                                                                                                                                                                                                                                                                                                                                                                                                                                         3. LVEF\                                                           3. P \< 0.001\
                                                                                                                                                                                                                                                                                                                                                                                                                                         4. Cardiovascular mortality\                                       4. P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         5. Myocardial infarction rate                                      5. P \< 0.05

  [@B75]          The guideline of unstable angina pectoris from ACCF/AHA USA, 2007                  109 (72/37)\                                             110 (74/36)\         Danlou tablet (4.5g, qd, p.o).                                        Placebo                 Antiplatelet, aggregation, anticoagulant, lipid-lowering, improvement of myocardial, remodeling, step-down                     90 days                  1\. Cardiovascular mortality\                                      1\. P \> 0.05\
                                                                                                     62.89 ± 9.23                                             63.89 ± 10.03                                                                                                                                                                                                                                                              2. Myocardial infarction rate\                                     2. P = 0.04\
                                                                                                                                                                                                                                                                                                                                                                                                                                         3. Reconstructive rate of blood vessels\                           3. P \> 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         4. Troponin\                                                       4. P \> 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         5. hsCRP                                                           5. P \> 0.05

  [@B102]         The guideline of chronic stable angina from China, 2007                            76 (48/28)\                                              74 (46/28)\          Traditional Chinese medicine prescription (10 mg, tid, p.o).          Placebo                 Isosorbide, aspirin, atorvastatin                                                                                              4 weeks                  1\. The efficiency of angina pectoris\                             1\. P \< 0.05\
                                                                                                     51.8 ± 1.6                                               51. 5 ± 1. 4                                                                                                                                                                                                                                                               2. Electrocardiogram efficiency\                                   2. P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         3. TG\                                                             3. P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         4. TC\                                                             4. P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         5. HDL-C\                                                          5. P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         6. LDL-C\                                                          6. P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         7. TCM syndrome score                                              7. P \< 0.05\

  [@B74]          The guideline of unstable angina pectoris from ACC/AHA USA, 2011                   40 (17/23)\                                              40 (21/19)\          Xuesaitong soft capsule (0.66g, bid, p.o).                            Placebo                 Conventional western medicine (unspecified)                                                                                    4 weeks                  1\. TC\                                                            1\. P \< 0.05\
                                                                                                     70.68 ± 6.87                                             71.65 ± 4.32                                                                                                                                                                                                                                                               2. TG\                                                             2. P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         3. HDL\                                                            3. P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         4. LDL\                                                            4. P \< 0.05\
                                                                                                                                                                                                                                                                                                                                                                                                                                         5. Survey of angina pectoris in Seattle                            5. P \< 0.05

  [@B89]          The guideline of chronic stable angina from China, 2014                            33 (20/13)\                                              33 (21/12)\          Coronary Ningtong prescription                                        Placebo                 Aspirin enteric-coated tablets, simvastatin tablets, isosorbide mononitrate, metoprolol                                        24 weeks                 1\. Coronary stenosis\                                             1\. P \< 0.05\
                                                                                                     61.18 ± 6.61                                             61.03 ± 7.51                                                                                                                                                                                                                                                               2. The efficiency of angina pectoris                               2. P \< 0.05
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PCI, percutaneous coronary intervention; LVEF, left ventricular ejection fraction; hsCRP, high sensitive C reactive protein; TC, total cholesterol; TG, total glycerol three fat; HDL, high density lipoprotein; LDL, low density lipoprotein; STEMI, segment elevation myocardial infarction; WHO, world health organization; NM, not mention; QSYQ, Qi-Shen-Yi-Qi dripping pills.

Study Quality {#s3_3}
-------------

The quality score of study ranged from 4 to 7 in a total of 7 points. Of which, six studies ([@B45]; [@B10]; [@B72]; [@B36]; [@B86]; [@B75]) got 7 points, three studies ([@B100]; [@B13]; [@B49]) got 6 points, 15 studies ([@B58]; [@B46]; [@B9]; [@B59]; [@B96]; [@B66]; [@B52]; [@B76]; [@B5]; [@B65]; [@B25]; [@B85]; [@B102]; [@B74]) got 5 points, and three studies ([@B43]; [@B67]; [@B89]) got 4 points. All 27 included studies had random allocation, including 10 ([@B58]; [@B9]; [@B59]; [@B52]; [@B76]; [@B5]; [@B43]; [@B67]; [@B102]) in which a random number table was used, eight ([@B45]; [@B10]; [@B72]; [@B66]; [@B77]; [@B36]; [@B13]; [@B74]) that employed a computer generated random sample set, three ([@B86]; [@B100]; [@B75]) that applied block randomization, and six ([@B46]; [@B96]; [@B65]; [@B25]; [@B85]; [@B49]) that stated that randomization was used without providing methodological details. Of the 27 included studies, all studies reported blinding of participants and personnel and withdraw bias. Additionally, nine studies ([@B45]; [@B10]; [@B72]; [@B36]; [@B86]; [@B100]; [@B13]; [@B49]; [@B75]) reported using allocation concealment; eight studies ([@B45]; [@B10]; [@B72]; [@B36]; [@B86]; [@B100]; [@B13]; [@B75]) applied blinding specifically during outcome measure assessment, and 22 studies ([@B45]; [@B58]; [@B46]; [@B9]; [@B10]; [@B59]; [@B72]; [@B96]; [@B66]; [@B52]; [@B76]; [@B5]; [@B65]; [@B25]; [@B36]; [@B85]; [@B86]; [@B49]; [@B75]; [@B102]; [@B74]) reported selective reporting. No study provided sample size estimation information. The methodological quality is concluded in [**Table 2**](#T2){ref-type="table"}.

###### 

Quality assessment of included studies.

  Study     A   B   C   D   E   F   G   Total
  --------- --- --- --- --- --- --- --- -------
  [@B45]    1   1   1   1   1   1   1   7
  [@B58]    1   0   1   0   1   1   1   5
  [@B46]    1   0   1   0   1   1   1   5
  [@B10]    1   1   1   1   1   1   1   7
  [@B9]     1   0   1   0   1   1   1   5
  [@B59]    1   0   1   0   1   1   1   5
  [@B72]    1   1   1   1   1   1   1   7
  [@B96]    1   0   1   0   1   1   1   5
  [@B66]    1   0   1   0   1   1   1   5
  [@B52]    1   0   1   0   1   1   1   5
  [@B76]    1   0   1   0   1   1   1   5
  [@B77]    1   0   1   0   1   1   1   5
  [@B5]     1   0   1   0   1   1   1   5
  [@B65]    1   0   1   0   1   1   1   5
  [@B43]    1   0   1   0   1   0   1   4
  [@B25]    1   0   1   0   1   1   1   5
  [@B36]    1   1   1   1   1   1   1   7
  [@B67]    1   0   1   0   1   0   1   4
  [@B85]    1   0   1   0   1   1   1   5
  [@B86]    1   1   1   1   1   1   1   7
  [@B100]   1   1   1   1   1   0   1   6
  [@B13]    1   1   1   1   1   0   1   6
  [@B49]    1   1   1   0   1   1   1   6
  [@B75]    1   1   1   1   1   1   1   7
  [@B102]   1   0   1   0   1   1   1   5
  [@B74]    1   0   1   0   1   1   1   5
  [@B89]    1   0   1   0   1   0   1   4

A, adequate sequence generation; B, concealment of allocation; C, blinding of participants and personnel; D, blinding of outcome assessment; E, incomplete out-come data; F, selective reporting; G, other bias; 1, low risk of bias, the information of the domain was adequate in the text; 0, high risk of bias, the information of the domain was inadequate in the text.

Effectiveness {#s3_4}
-------------

### The Incidence of MI and PCI {#s3_4_1}

Meta-analysis of 10 studies ([@B45]; [@B46]; [@B72]; [@B66]; [@B65]; [@B43]; [@B67]; [@B86]; [@B49]; [@B75]) found a significant difference in favor of CHM for decreasing the incidence of MI compared with control group (n = 9510, OR = 0.50, 95% CI (0.41, 0.63), P \< 0.00001, I^2\ =^ 0%) ([**Figure 2**](#f2){ref-type="fig"}). Meta-analysis of five studies ([@B45]; [@B46]; [@B72]; [@B65]; [@B75]) showed CHM existed significant effect for decreasing the incidence of PCI compared with control group (n = 8775, OR = 0.66, 95% CI (0.51, 0.86), P = 0.002, I^2^ = 0%) ([**Figure 3**](#f3){ref-type="fig"}).

![The forest plot: effects of Chinese herbal medicine for decreasing the incidence of myocardial infarction compared with control group.](fphar-10-00844-g002){#f2}

![The forest plot: effects of Chinese herbal medicine for decreasing the incidence of percutaneous coronary intervention compared with control group.](fphar-10-00844-g003){#f3}

Cardiovascular Mortality {#s3_5}
------------------------

Seven studies ([@B72]; [@B65]; [@B67]; [@B86]; [@B49]; [@B75]) reported cardiovascular mortality as the outcome measure. Of which, there were no deaths were found in three studies ([@B46]; [@B72]; [@B75]). Meta-analysis of remaining four studies ([@B65]; [@B67]; [@B86]; [@B49]) showed CHM existed significant effect for decreasing cardiovascular mortality compared with control group (n = 9,060, OR = 0.73, 95% CI: 0.58,0.93, P = 0.009, I^2^ = 15%) ([**Figure 4**](#f4){ref-type="fig"}).

![The forest plot: effects of Chinese herbal medicine for decreasing the cardiovascular mortality compared with control group.](fphar-10-00844-g004){#f4}

### Systolic and Diastolic Functions of the Heart in Cardiac Ultrasound and the Level of ST-Segment Depression in Electrocardiogram {#s3_5_1}

For systolic function, five studies ([@B58]; [@B59]; [@B5]; [@B67]; [@B49]) showed CHM existed significant effect for increasing LVEF compared with control group (P \< 0.05). For diastolic function, there was no study involving related indicators as outcome measure. Two studies ([@B58]; [@B5]) showed that CHM could decrease the ventricular wall motion score compared with control (P \< 0.05). In addition, meta-analysis of three studies ([@B10]; [@B25]; [@B67]) reported that CHM can increase degree of decline in the ST-segment compared with control (n = 473, OR = 2.51, 95% CI: 1.64∼3.83, P \< 0.0001, I^2^ = 0%) ([**Figure 5**](#f5){ref-type="fig"}).

![The forest plot: effects of Chinese herbal medicine for increasing degree of decline in the ST segment compared with control group.](fphar-10-00844-g005){#f5}

### Clinical Efficacy {#s3_5_2}

Compared with controls, meta-analysis of 12 studies ([@B45]; [@B10]; [@B66]; [@B52]; [@B76]; [@B25]; [@B43]; [@B67]; [@B100]; [@B13]; [@B102]; [@B89]) showed that the efficiency of angina improved more obviously in the TCM group than that in the control group (n = 1711, OR = 0.21, 95% CI: 0.17∼0.26, P = 0.09, I^2^ = 41%) ([**Figure 6**](#f6){ref-type="fig"}); two studies ([@B67]; [@B85]) for reducing the usage of nitroglycerin (n = 242, MD = -0.71, 95%CI: -0.91∼-0.51, P \< 0.00001, I^2^ = 0%) ([**Figure 7**](#f7){ref-type="fig"}), four studies ([@B46]; [@B77]; [@B102]; [@B74]) for reducing LDL (n = 5,248, SMD = -0.67, 95%CI: -0.73∼-0.61, P \< 0.00001,I^2^ = 0%) ([**Figure 8**](#f8){ref-type="fig"}), two studies ([@B52]; [@B76]) for reducing hsCRP (n = 182, OR = -0.95, 95% CI: -1.26∼0.64, P \< 0.00001, I^2^ = 0%) ([**Figure 9**](#f9){ref-type="fig"}), two studies ([@B45]; [@B89]) for reducing the degree of coronary artery stenosis (P \< 0.05), and two studies ([@B66]; [@B43]) for reducing the rate of coronary restenosis (P \< 0.05).

![The forest plot: effects of Chinese herbal medicine for improving the efficiency of angina compared with control group.](fphar-10-00844-g006){#f6}

![The forest plot: effects of Chinese herbal medicine for reducing the usage of nitroglycerin compared with control group.](fphar-10-00844-g007){#f7}

![The forest plot: effects of Chinese herbal medicine for reducing low density lipoprotein.](fphar-10-00844-g008){#f8}

![The forest plot: effects of Chinese herbal medicine for reducing hypersensitive C-reactive protein.](fphar-10-00844-g009){#f9}

The Safety of Co-Administration of CHM {#s3_6}
--------------------------------------

Adverse events were reported in 11 studies ([@B45]; [@B10]; [@B72]; [@B96]; [@B66]; [@B65]; [@B67]; [@B100]; [@B75]; [@B102]; [@B89]), analyzed but not observed in four studies ([@B46]; [@B9]; [@B5]; [@B36]), and not analyzed in 12 studies ([@B58]; [@B59]; [@B52]; [@B76], [@B77]; [@B43]; [@B25]; [@B85]; [@B86]; [@B13]; [@B49]; [@B74]). In the 11 studies with adequate information about adverse events, a total of 106/5,134 (2.06%) patients suffered adverse events in the treatment groups and 118/5,167 (2.28%) patients in control groups. Gastrointestinal discomfort symptoms, including nausea, stomachache, vomiting, diarrhea, anorexia, and constipation, were the most frequently occurring adverse events, affecting 74/106 (69.8%) patients in the treatment groups and 80/118 (67.8%) in control group patients. Allergy, hemorrhage, hepatic insufficiency, headache, and urinary tract infection were reported frequently also, affecting 20/106 (18.8%) patients in the treatment groups and 26/118 (22.0%) of patients in the control groups. The majority of above adverse events were mild and resolved by stopping related drugs and symptomatic treatment. Although some serious adverse events such as heart failure (1/106), cerebral hemorrhage (1/106), pericardial tamponade (1/106), coronary bypass surgery (1/106), and death (1/106) were reported in the two groups, there was no significant difference between the two groups.

Ingredients of CHM Formulae and Frequently Used Herbs {#s3_7}
-----------------------------------------------------

The ingredients of CHM in each RCT are listed in [**Table 3**](#T3){ref-type="table"}. The most frequently used herbs across all formulae were *Miltiorrhiza* (nine formulae), pseudo-ginseng (seven formulae), ginseng (seven formulae), *Radix Paeoniae rubra* (six formulae), *Astragalus membranaceus* (five formulae), rhizome of *Chuanxiong* (five formulae), leech (five formulae), borneol (five formulae), and safflower (four formulae). Chinese *Angelica*, *Achyranthes bidentata*, *Rehmannia glutinosa*, peach kernel, liquorice, hawthorn, *Trichosanthes*, *Cinnamomum*, *Poria*, aloes, *Rhizoma Corydalis*, and ginkgo biloba were also frequently used.

###### 

Ingredients of Chinese herbal medicine formulae.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study (years)        Prescription                                  Ingredients of herb prescription                                                                                                                                                                                                                                                                                                                                                                                 Usage of prescription    Preparations   Quality control
  -------------------- --------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------ -------------- ----------------------------------------------------------------------------------------------------
  [@B10]               Xuefu Zhuyu capsule                           Peach kernel, *Angelica sinensis*, rhizome of *Chuanxiong*, safflower, *Radix Paeoniae rubra*, *Radix Rehmanniae*, *Fructus aurantii*, *Radix Bupleuri*, *Platycodon grandiflorum*, *Radix Achyranthis bidentatae*, and liquorice                                                                                                                                                                                3\#tid po                Capsule        Traditional Chinese patented medicine WY: Z12020223

  [@B58]\              Tongguan capsule                              *Astragalus membranaceus*, *Miltiorrhiza*, leech, etc.                                                                                                                                                                                                                                                                                                                                                           3\#tid po                Capsule        Produced by The Second Affiliated Hospital Of Guangzhou University Of Traditional Chinese Medicine
  [@B5]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  [@B9]                Qingre Quyu granule                           *Fructus trichosanthis* 15g, *Miltiorrhiza* 30g, hawthorn 30g, *Fritillaria thunbergii* 10g, pseudo-ginseng 3g, *Lignum Millettiae* 30g, and the seed of cowherb 15g                                                                                                                                                                                                                                             1\#bid po                Decoction      Produced by China Pharmaceutical Materials Group Company

  [@B45] [@B66]        Xiongshao capsule                             Rhizome of *Chuanxiong* and Radix *Paeoniae rubra*                                                                                                                                                                                                                                                                                                                                                               2\#tid po                Capsule        Unreported

  [@B74]               Xuesaitong soft capsule                       Pseudo-ginseng                                                                                                                                                                                                                                                                                                                                                                                                   2\#bid po                Capsule        Traditional Chinese patented medicine WY: Z19990022

  [@B52]               Yixin Mai granule                             Ginseng, cassia twig, *Fructus trichosanthis*, leech, and *Poria cocos*                                                                                                                                                                                                                                                                                                                                          1\#tid po                Decoction      Produced by Ruikang Hospital Affiliated to Guangxi College of Traditional Chinese Medicine

  [@B36]               Red ginseng Tongxin granule                   *Radix Paeoniae rubra* 10g, Agilawood 1g, *Angelica sinensis* 10g, orange peel 10g, *Rhizoma Corydalis* 6g, rhizome of *Chuanxiong* 6g, *Miltiorrhiza* 10g, astragalus 6g, peach kernel 10g, and safflower 10g                                                                                                                                                                                                   Unreported               Decoction      Produced by Jiangyin Tianjiang Pharmaceutical Co., Ltd.

  [@B102]              Traditional Chinese medicine prescription     Hawthorn, *Miltiorrhiza*, ginkgo leaf, lentil, *Psoralea*, sapanwood, *Ganoderma*, *Polygonum multiflorum*, *Cornus officinalis*, *Alisma orientalis*, *Radix Paeoniae alba*, cinnamon, *Pericarpium Citri reticulatae*, liquorice, *Fructus cnidii*, cicada slough, and *Ramuli Umcariae Cumuncis*                                                                                                              1\#tid po                Capsule        Unreported

  [@B72]               Shenshao tablet                               Radix *Paeoniae alba* and ginseng                                                                                                                                                                                                                                                                                                                                                                                4\#tid po                Tablet         Traditional Chinese patented medicine WY: Z19990059

  [@B86]\              Shenzhu Guanxin recipe                        Ginseng 5g, *Rhizoma Atractylodis* 10g, *Radix Notoginseng* 10g, *Rhizoma Pinelliae* 10g, leech 3g, *Radix Panacis quinquefolium* 5g, and *Folium nelumbinis* 15g                                                                                                                                                                                                                                                50ml qd po               Decoction      Produced by Jiangxi Jiangyin Pharmaceutical Factory
  [@B84]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Wang et al., 2012\   Danlou tablet                                 *Fructus trichosanthis*, *Allium macrostemon*, the root of kudzu vine, rhizome of *Chuanxiong*, *Miltiorrhiza*, *Radix Paeoniae rubra*, *Alisma orientalis*, *Astragalus membranaceus*, *Curcuma aromatica*, and *Drynaria* rhizome                                                                                                                                                                              4.5g qd po               Tablet         Traditional Chinese patented medicine WY: YBZ17382006
  [@B75]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  [@B49]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  [@B96]\              Tongxinluo capsule                            Ginseng, leech, scorpion, red peony root, cicada slough, soil turtle worm, centipede, sandalwood, *Lignum acronychiae*, frankincense, jujube nut, and borneol                                                                                                                                                                                                                                                    Before PCI: 8\# qd po\   Capsule        Traditional Chinese patented medicine WY: Z19980015
  [@B43]                                                                                                                                                                                                                                                                                                                                                                                                                                                                              After PCI: 4\#tid po                    

  [@B59]               Compound *Salvia* tablet and Xinyue capsule   *Miltiorrhiza* 450mg, pseudo-ginseng 141mg, borneol 8mg, ginseng 50mg                                                                                                                                                                                                                                                                                                                                            Unreported               Capsule        Traditional Chinese patented medicine WY: Z44023372 and Z20030073

  [@B25]               Kodaling tablet                               Rhizoma *Corydalis*                                                                                                                                                                                                                                                                                                                                                                                              3\#tid po                Tablet         Produced by Zhejiang KangEnbei Pharmaceutical Co., Ltd.

  [@B13]               Live heart pill                               Ginseng, *Radix Aconiti carmichaeli*, *Ganoderma lucidum*, safflower, musk, bezoar, bear bile, pearl, toad venom, and borneol                                                                                                                                                                                                                                                                                    2\#tid po                Tablet         Traditional Chinese patented medicine WY: Z44021835

  [@B100]              Wufuxinnaoqing                                Safflower oil, borneol, vitamin E, and vitamin B6                                                                                                                                                                                                                                                                                                                                                                2\#tid po                Capsule        Produced by Shineway Pharmaceutical Group Co., Ltd.

  [@B46]               Xuezhikang capsule                            Red yeast Chinese rice                                                                                                                                                                                                                                                                                                                                                                                           600mg bid po             Capsule        Produced by the Beijing WBL Peking\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              University Biotech Co. Ltd.

  [@B65]               Qi-Shen-Yi-Qi dripping pills                  *Miltiorrhizae*, pseudo-ginseng, *Lignum Dalbergiae odoriferae*, and *Astragalus membranaceus*                                                                                                                                                                                                                                                                                                                   0.5g tid po              Pill           Unreported in detail

  [@B89]               Coronary Ningtong prescription                *Astragalus membranaceus* 30g, *Miltiorrhiza* 30g, mulberry parasitism 30g, *Gynostemma pentecox* 30g, hawthorn 30g, the root of kudzu vine 30g, Herba *Rhodiolae* 30g, *Fructus trichosanthis* 15g, *Allium macrostemon* 15g, *Rhizoma Pinellinae praeparata* 15g, immature bitter orange 10g, safflower 10g, *Rhizoma Sparganii* 10g, *Zedoaria* 10g, *Rhizoma coptidis* 6g, pseudo-ginseng 3g, and leech 3g   100ml bid po             Decoction      Unreported

  [@B67]               Musk Baoxin pill                              artificial musk, ginseng, cinnamon, toad venom, storax, artificial bezoar, and borneol                                                                                                                                                                                                                                                                                                                           2\#tid po                Pill           Produced by Shanghai and Huangyao Pharmaceutical Industry

  Wang et al., 2012    Double ginseng capsule And Tongguan capsule   *Miltiorrhiza*, ginseng, *Herba Rhodiolae*, pseudo-ginseng and *Lignum Dalbergiae odoriferae*                                                                                                                                                                                                                                                                                                                    4\#tid po                Capsule        Produced by Shaanxi Pharmaceutical Group Shaanxi New Drug Technology Development Center
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

d, day; \#: tablet; PCI, Percutaneous Coronary Intervention; Co., Ltd, Company Limited.

Possible Mechanism of Herbal Benefits for CHD {#s3_8}
---------------------------------------------

A total of 45 experimental studies ([@B27]; [@B42]; [@B7]; [@B20]; [@B54]; [@B73]; [@B37]; [@B37]; [@B69]; [@B96]; [@B34]; [@B39]; [@B55]; [@B82]; [@B94]; [@B35]; [@B47]; [@B101]; [@B33]; [@B71]; [@B79]; [@B91]; [@B98]; [@B21]; [@B31]; [@B36]; [@B56]; [@B57]; [@B68]; [@B70]; [@B80]; [@B88]; [@B97]; [@B12]; [@B44]; [@B78]; [@B83]; [@B92]; [@B6]; [@B15]; [@B26]; [@B30]; [@B48]; [@B51]; [@B93]) were identified in our electronic searches to investigate the effects and mechanisms of the main active components of single flavored Chinese medicine which were frequently used on I/R injury models ([**Table 4**](#T4){ref-type="table"}). The possible mechanisms of them are summarized as follows: (1) oxidative stress is important reaction after myocardial ischemia. The function of free radical scavenging system is decreased in myocardial ischemia. Large amounts of free radicals was produced by the unbalanced endogenous antioxidant systems, which further leads to the peroxidation of lipids, proteins and nucleic acids, the biochemical alteration (reducing SOD, and GSH-Px, and increasing MDA), and further led to cardiomyocyte death ([@B90]). Based on these observations, antioxidant therapy is the key step considered to prevent I/R injury. In our study, *Salvia miltiorrhiza*, salvianolic acid B, tanshinone IIA, notoginsenoside R1, ginsenoside Rb1, ginsenoside Rb3, astragaloside IV, and ligustrazine could enhance SOD ([@B4]; [@B47]; [@B36]; [@B68]; [@B88]; [@B78]; [@B83]) and attenuate chondriokinesis to reduce the release of MDA ([@B39]; [@B4]; [@B36]; [@B68]; [@B88]; [@B83]); borneol, ginsenoside Rd, and hydroxysafflor yellow A could reduce ROS ([@B20]; [@B34]; [@B79]). *S. miltiorrhiza* and hydroxysafflor yellow A ([@B26]) exhibit antioxidant effects *via* PI3K/Akt signaling pathway; tanshinone IIA ([@B80]) increases NADPH oxidase *via* AMPK/Akt/PKC pathway; and astragaloside IV ([@B97]) could reduce ROS *via* the PI3K/Akt/mTOR pathway. Our study showed TCM could improve the antioxidant function to reduce the damage of myocardial ischemia. (2) Apoptosis was an energy-requiring programmed cell death ([@B95]). Apoptosis can be activated extrinsically by sarcolemmal receptors such as FAS: FAS(CD 95) and tumor necrosis factor alpha (TNF-α) ([@B29]), or intrinsically by cytochrome c which initiates the caspase cascade activation result in intracellular proteolysis. In addition, the opening of mitochondrial permeability transition pore (MPTP) conduces the mitochondrial matrix swelling, then leading to rupture of the outer membrane and release of cytochrome c, activating the caspase cascade, ultimately resulting in the apoptotic cell death ([@B23]). Proapoptotic and antiapoptotic proteins of the Bcl family interact with the MPTP ([@B2]). In present study, *S. miltiorrhiza*, salvianolic acid A, salvianolic acid B, paeonol, paeoniflorin, ginsenoside Rb1, ginsenoside Rb3, ginsenoside Rd, ginsenoside Rg3, and ligustrazine could increase Bcl-2 expression ([@B54]; [@B73]; [@B69]; [@B94]; [@B79]; [@B36]; [@B78]; [@B15]) and the Bcl-2/Bax ratio ([@B54]; [@B69]; [@B82]; [@B94]; [@B79]; [@B36]; [@B78]; [@B6]; [@B15]). Three studies ([@B73]; [@B98]; [@B6]) reported that salvianolic acid A, tanshinone IIA, and ginsenoside Rb1 exhibit anti-apoptotic effects *via* PI3K/Akt signaling pathway, and one study ([@B79]) reported that ginsenoside Rd could decrease caspase-3 and caspase-9 activities. (3) The inflammation during myocardial I/R injury was reviewed by previous studies ([@B50]). The excessive inflammation can lead to cardiomyocyte damage. When the myocardium got reperfused, the NF-κB pathway was activated by pattern recognition receptors, culminating in promoted cytokine expression. *S. miltiorrhiza*, tanshinone I, tanshinone IIA, paeonol, notoginsenoside r1, ginsenoside Re, ginsenoside Rg1, ligustrazine, astragaloside IV, and astragalus polysaccharides were shown to exert anti-inflammatory effects by decreasing TNF-alpha ([@B96]; [@B33]; [@B71]; [@B12]; [@B44]; [@B83]), IL-6 ([@B7]; [@B96]), IL-8 ([@B31]), and NF-κB ([@B71]; [@B57]; [@B12]; [@B44]). Two studies ([@B57]; [@B101]) reported that ligustrazine and astragalus polysaccharides exhibit anti-inflammatory effects *via* inhibiting P38MAPK pathway, and one study ([@B96]) reported that tanshinone IIA could decrease TNF-alpha and IL-6 *via* PI3K/Akt pathway. (4) Nitric oxide is an essential modulator of cardiovascular system. The NO can decrease intracellular calcium concentration in vascular smooth muscle cells, which further induces vasodilation ([@B64]). Salvianolic acid B, tanshinone IIA, ginsenoside Rb1, ginsenoside Rg3, ligustrazine, astragaloside IV, and hydroxysafflor yellow A were shown to improve circulation by increasing NO expression ([@B42]; [@B37]; [@B55]; [@B47]; [@B30]; [@B78]) *via* up-regulating eNOS phosphorylation ([@B42]; [@B37]; [@B55]; [@B47]; [@B30]; [@B78]). (5) *S. miltiorrhiza* and notoginsenoside r1 were shown to regulate energy metabolism *via* p-JNK-NF-kappaB-TRPC6 pathway ([@B51]) and ROCK-dependent ATP5D modulation separately ([@B21]; [@B31]). (6) Hirudin was shown to attenuate coagulation and enhance microvascular flow during reperfusion ([@B27]). Thus, antioxidant, anti-apoptotic, circulation improvement, anti-inflammatory, and energy metabolism regulation actions have been promoted as important mechanisms of herbal compounds used to treat I/R injury.

###### 

Mechanisms of the main active components of single flavored Chinese Medicine on organic injury induced by ischemia/reperfusion.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Active ingredients           Herb source               Possible mechanisms (signaling pathway)                                                                                                                                 Citation                     Structure
  ---------------------------- ------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------- ------------------------------
  Salvia miltiorrhiza          Miltiorrhiza              1\. Regulation of energy metabolism (p-JNK-NF-kappaB-TRPC6 pathway)\                                                                                                    1\. [@B51]\                  ![](fphar-10-00844-g010.jpg)
                                                         2. Attenuation of oxidative stress (Akt/Nrf2/HO-1 pathway)\                                                                                                             2. [@B26]\                   
                                                         3. Anti-inflammation\                                                                                                                                                   3. [@B91]\                   
                                                         4. Anti-apoptosis (increase expression of Bcl-2 and increase Bcl-2/Bax ratio, affect Akt, and ERK1/2 phosphorylation)                                                   4. [@B92]; [@B15]            

  Salvianolic acid A           Miltiorrhiza              1\. Anti-apoptosis (increase Bcl-2/Bax ratio *via* JNK/PI3K/Akt signaling pathway)                                                                                      1\. [@B6]                    ![](fphar-10-00844-g011.jpg)

  Salvianolic acid B           Miltiorrhiza              1\. Improve circulation (increase expression of NO *via* up-regulating eNOS phosphorylation)\                                                                           1\. [@B55]\                  ![](fphar-10-00844-g012.jpg)
                                                         2. Attenuation of oxidative stress (increase SOD and decrease MDA)\                                                                                                     2. [@B88]\                   
                                                         3. Anti-apoptosis                                                                                                                                                       3. [@B88]                    

  Tanshinone I                 Miltiorrhiza              1\. Anti-inflammation                                                                                                                                                   1\. [@B56]                   ![](fphar-10-00844-g013.jpg)

  Tanshinone IIA               Miltiorrhiza              1\. Improve circulation (increase expression of NO *via* up-regulating eNOS phosphorylation)\                                                                           1\. [@B55]\                  ![](fphar-10-00844-g014.jpg)
                                                         2. Attenuation of oxidative stress (increase SOD and HO-1, decrease MDA, increase NADPH oxidase *via* AMPK/Akt/PKC pathway)\                                            2. [@B68]; [@B80]\           
                                                         3. Anti-inflammation (decrease TNF-alpha and IL-6 *via* PI3K/Akt-dependent pathway)\                                                                                    3. [@B96]\                   
                                                         4. Anti-apoptosis (decrease caspase-3 activity *via* Akt/FOXO3A/Bim-mediated signal pathway)                                                                            4. [@B98]                    

  Paeonol                      Radix Paeoniae rubra      1\. Anti-inflammation\                                                                                                                                                  1\. [@B48]\                  ![](fphar-10-00844-g015.jpg)
                                                         2. Anti-apoptosis (increase expression of Bcl-2 and increase Bcl-2/Bax ratio)                                                                                           2. [@B54]                    

  Paeoniflorin                 *Radix Paeoniae rubra*    1\. Anti-apoptosis (increase expression of Bcl-2 and increased Bcl-2/Bax ratio)                                                                                         1\. [@B69]                   ![](fphar-10-00844-g016.jpg)

  Notoginsenoside r1           Pseudo-Ginseng            1\. Anti-inflammation (decrease IL-6, IL-8, and TNF-alpha)\                                                                                                             1\. [@B7]; [@B31]; [@B83]\   ![](fphar-10-00844-g017.jpg)
                                                         2. Regulation of energy metabolism (ROCK-dependent ATP5D modulation)\                                                                                                   2. [@B21]; [@B31]\           
                                                         3. Anti-apoptosis (increase Bcl-2 expression)\                                                                                                                          3. [@B37]\                   
                                                         4. Attenuation of oxidative stress (increase SOD, and decrease MDA)\                                                                                                    4. [@B83]\                   
                                                         5. Attenuation of endoplasmic reticulum stress                                                                                                                          5. [@B93]                    

  Ginsenoside Rb1              Ginseng                   1\. Anti-apoptosis (increase Bcl-2 expression and increased Bcl-2/Bax ratio *via* PI3K/Akt pathway)\                                                                    1\. [@B73]; [@B82]\          ![](fphar-10-00844-g018.jpg)
                                                         2. Attenuation of oxidative stress (increase SOD, and decrease MDA)\                                                                                                    2. [@B4]\                    
                                                         3. Improve circulation (increase NO expression *via* up-regulating eNOS phosphorylation)                                                                                3. [@B30]                    

  Ginsenoside Rb3              Ginseng                   1\. Attenuation of oxidative stress (increase SOD, and decrease MDA)\                                                                                                   1\. [@B36]\                  ![](fphar-10-00844-g019.jpg)
                                                         2. Anti-apoptosis (increase Bcl-2 expression and increase Bcl-2/Bax ratio)                                                                                              2. [@B36]                    

  Ginsenoside Rd               Ginseng                   1\. Attenuation of oxidative stress (decrease ROS)\                                                                                                                     1\. [@B79]\                  ![](fphar-10-00844-g020.jpg)
                                                         2. Anti-apoptosis (increase Bcl-2 expression and increase Bcl-2/Bax ratio, decrease caspase-3 and caspase-9 activity *via* mitochondrial-dependent apoptotic pathway)   2. [@B79]                    

  Ginsenoside Re               Ginseng                   1\. Anti-inflammation (decrease TNF-alpha)                                                                                                                              1\. [@B33]                   ![](fphar-10-00844-g021.jpg)

  Ginsenoside Rg1              Ginseng                   1\. Anti-inflammation (decrease TNF-alpha and IL-1beta, in part *via* the NF-κB signaling pathway)                                                                      1\. [@B70]; [@B12]           ![](fphar-10-00844-g022.jpg)

  Ginsenoside Rg3              Ginseng                   1\. Attenuation of oxidative stress (increase SOD)\                                                                                                                     1\. [@B78]\                  ![](fphar-10-00844-g023.jpg)
                                                         2. Anti-apoptosis (increase Bcl-2 expression and increase Bcl-2/Bax ratio)\                                                                                             2. [@B78]\                   
                                                         3. Improve circulation (increase NO expression *via* up-regulating eNOS phosphorylation)                                                                                3. [@B78]                    

  Borneol                      Borneol                   1\. Attenuation of oxidative stress (decrease ROS)                                                                                                                      1\. [@B34]                   ![](fphar-10-00844-g024.jpg)

  Ligustrazine                 Rhizome of *Chuanxiong*   1\. Attenuation of oxidative stress (increase SOD and decrease MDA)\                                                                                                    1\. [@B39]; [@B47]\          ![](fphar-10-00844-g025.jpg)
                                                         2. Improve circulation (increase NO expression *via* up-regulating eNOS phosphorylation)\                                                                               2. [@B47]\                   
                                                         3. Anti-inflammation (decrease the expression of NF-κB *via* inhibiting P38MAPK pathway)\                                                                               3. [@B57]\                   
                                                         4. Anti-apoptosis (increase Bcl-2 expression and increase Bcl-2/Bax ratio)                                                                                              4. [@B94]                    

  Astragaloside IV             Astragalus membranaceus   1\. Promoting angiogenesis (increase the expression of VEGF)\                                                                                                           1\. [@B92]\                  ![](fphar-10-00844-g026.jpg)
                                                         2. Anti-apoptosis (increase Bcl-2 expression and increase Bcl-2/Bax ratio, decrease caspase-3)\                                                                         2. [@B71]; [@B44]\           
                                                         3. Anti-inflammation (decrease the expression of TNF-alpha and NF-κB)\                                                                                                  3. [@B71]; [@B44]\           
                                                         4. Improve circulation (increase NO expression *via* up-regulating eNOS phosphorylation)\                                                                               4. [@B37]\                   
                                                         5. Attenuation of oxidative stress (reduce ROS to *via* the PI3K/Akt/mTOR pathway)                                                                                      5. [@B97]                    

  Astragalus polysaccharides   Astragalus membranaceus   1\. Anti-inflammatory (*via* the p38 MAPK signaling pathway)                                                                                                            1\. [@B101]                  ![](fphar-10-00844-g027.jpg)

  Hirudin                      Leech                     1\. Attenuate coagulation and enhance microvascular flow during reperfusion                                                                                             1\. [@B27]                   ![](fphar-10-00844-g028.jpg)

  Hydroxysafflor yellow A      Safflower                 1\. Attenuation of oxidative stress (Akt/Nrf2/HO-1 pathway, decrease ROS)\                                                                                              1\. [@B20]; [@B26]\          ![](fphar-10-00844-g029.jpg)
                                                         2. Improve circulation (increase NO expression *via* up-regulating eNOS phosphorylation)                                                                                2. [@B42]                    
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

HO-1, heme oxygenase-1; SOD, super oxide dismutase; PI3K, phosphatidylinositol 3-kinase; ROS, reactive oxygen species; eNOS, endothelial nitric oxide synthase; MDA, malonaldehyde; NADPH, nicotinamide adenine dinucleotide phosphate; VEGF, vascular endothelial growth factor; NF-κB, nuclear factor κB.

Discussion {#s4}
==========

Summary of Evidence {#s4_1}
-------------------

This is the first clinical systematic review of 27 high-quality RCTs involving 11,732 participants to estimate the efficacy and safety of CHMs for CHD. The evidence available from present study revealed that CHMs are beneficial for CHD and are generally safe. In addition, CHM exerted cardioprotection for CHD, possibly altering multiple signal pathways through anti-inflammation, anti-oxidation, anti-apoptosis, circulation improvement, and energy metabolism regulation.

Limitations {#s4_2}
-----------

First, there were still some methodological weaknesses in the primary studies although we included high-quality studies. Only nine of the 27 included studies ([@B45]; [@B10]; [@B72]; [@B36]; [@B86]; [@B100]; [@B13]; [@B49]; [@B75]) reported allocation concealment, and eight included studies ([@B45]; [@B10]; [@B72]; [@B36]; [@B86]; [@B100]; [@B13]; [@B75]) reported blinding during outcome assessment. It is worth noting that an average 18% more "beneficial" effect in trials with inadequate or unclear concealment of allocation compared with adequate concealment ([@B24]). And blinding during outcome assessment is an essential method to avoid systemic errors which existed in the outcome assessment of non-blinded studies ([@B24]). Second, English and Chinese literatures were included only in present study and the absence of studies written in other languages may generate selective bias in a certain degree. Third, no included trials were reported to have been registered, and negative findings were less likely to be published, which may lead to the efficacy being overestimated.

Implications {#s4_3}
------------

The findings from present study indicate that CHM paratherapy is beneficial for CHD and is well tolerated. Thus, we recommended, at least to an extent, to use CHMs for CHD, especially selected case. Further study should identify specific CHM and/or indications of CHM. In addition, the findings of the most frequently used herbs such as *Miltiorrhiza*, pseudo-ginseng, ginseng, *Radix Paeoniae rubra*, *Astragalus membranaceus*, rhizome of *Chuanxiong*, leech, borneol, and safflower and their main active components should be considered as further development of herbal prescriptions and component injection for CHD.

Some methodological weaknesses still existed in the primary studies. Recommendations for further research are as follows: (1) the CONSORT 2010 statement ([@B63]), CONSORT for TCM ([@B3]), RCTs investigating CHM ([@B16]), and CONSORT Extension for Chinese Herbal Medicine Formulas 2017 ([@B8]) should be abided by for the design. (2) Clinic trials should be registered in a generally accessible database ([www.clinicaltrials.com](www.clinicaltrials.com)) prior to first case inclusion. It allows verification of predefined study hypothesis and end-points of the study, which would help to the report of negative findings and reduce publication bias ([@B61]). (3) In view of trials with insufficient statistical power that runs the risk of over estimating therapeutic efficacy ([@B28]), the further studies are recommended to provide statistical information of sample size estimation. (4) In order to ensure the efficacy of TCM, the identity and quantity of the herbal preparations should be described clearly in further research. (5) The safety of TCM has been increasingly concerned by both medical workers and the public.

The frequency of use for particular herb was calculated and those used at a high frequency that are described in detail in the part 3.6 and [**Table 3**](#T3){ref-type="table"}. The high-frequency herbs that we selected can ignite *the treatment based on syndrome differentiation* according to the herbal functions [**Table 5**](#T5){ref-type="table"}. Ginseng and *Astragalus membranaceus* benefit qi; *Miltiorrhiza*, pseudo-ginseng, *Radix Paeoniae rubra*, rhizome of *Chuanxiong*, leech, and safflower promote blood circulation for removing blood stasis; and borneol has function of resuscitation with aromatics for relieving pain. Thus, we can also deduce that the main patterns of CHD are qi deficiency and blood stasis. The selected high-frequency herbs are composed of a herbal prescription for CHD, which can be used for clinic and as a candidate for RCT.

###### 

Different syndromes of coronary heart disease and the classification of herbs according to syndrome differentiation therapy for different syndromes.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Syndrome                                          Syndrome differentiation therapy for different syndromes      Representative herbs in the theory of traditional Chinese medicine mentioned in present study
  ------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Syndrome of coagulation cold in heart vessel      1\. Dispelling cold\                                          1\. Cinnamon, *Psoralea*, *Ramuli Umcariae Cumuncis*\
                                                    2. Dredging channel blockade and yang                         2. *Angelica sinensis*, radix *Paeoniae rubra*, pseudo-ginseng, rhizome Of *Chuanxiong*, frankincense, *Miltiorrhiza*, safflower, peach kernel, rhizoma *Corydalis*, leech, soil turtle worm, *Lignum Millettiae*, ginkgo leaf, sapanwood, red yeast Chinese, *Allium macrostemon*

  Syndrome of qi stagnation in heart and chest      1\. Dispersing stagnated liver qi for regulating qi-flowing   1\. Hawthorn, *Fructus aurantii*, *Lignum acronychiae*, Agilawood, radix *Bupleuri*, rhizoma *Corydalis*

  Syndrome of blockade of heart blood               1\. Promoting blood circulation for removing blood stasis     1\. *Angelica sinensis*, radix *Paeoniae rubra*, pseudo-ginseng, rhizome Of *Chuanxiong*, frankincense, *Miltiorrhiza*, safflower, peach kernel, rhizoma *Corydalis*, leech, soil turtle worm, *Lignum Millettiae*, ginkgo leaf, sapanwood, red yeast Chinese rice

  Syndrome of turbid phlegm blocking heart          1\. Dredging yang for resolving turbidity\                    1\. *Allium macrostemon*\
                                                    2. Eliminating phlegm for resolving masses                    2. *Rhizoma Pinelliae*, liquorice, *Platycodon grandiflorum*, *Fritillaria thunbergii*, orange peel

  Syndrome of deficiency of both qi and yin         1\. Benefiting qi and nourishing yin\                         1\. *Angelica sinensis*, ginseng, *Astragalus Membranaceus*, radix *Panacis quinquefolium*, *Rhizoma Atractylodis*, liquorice\
                                                    2. Promoting blood circulation for dredging vessels           2. *Radix Paeoniae Rubra*, pseudo-ginseng, rhizome Of *Chuanxiong*, frankincense, *Miltiorrhiza*, safflower, peach kernel, rhizoma *Corydalis*, leech, soil turtle worm, *Lignum Millettiae*, ginkgo leaf, sapanwood, red yeast Chinese rice, musk

  Syndrome of yin deficiency of heart and kidney    1\. Nourishing yin and clearing heat\                         1\. *Angelica sinensis*, borneol, *Cassia* twig, cicada slough, *Fructus trichosanthis*, *Fritillaria thunbergii*, orange peel, *Folium nelumbinis*, bezoar, bear bile, pearl, toad venom, *Gynostemma pentecox*, *Rhizoma Coptidis*, liquorice\
                                                    2. Activating blood circulation for nourishing heart          2. *Radix Paeoniae rubra*, pseudo-ginseng, rhizome of *Chuanxiong*, frankincense, *Miltiorrhiza*, safflower, peach kernel, rhizoma *Corydalis*, leech, soil turtle worm, *Lignum Millettiae*, ginkgo leaf, sapanwood, red yeast Chinese rice

  Syndrome of yang deficiency of heart and kidney   1\. Warmly tonifying yang qi and inspiring heart yang         1\. Ginseng, *Astragalus Membranaceus*, radix *Panacis quinquefolium, Rhizoma Atractylodis*, liquorice, *Ganoderma*, *Herba Rhodiolae*
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cardioprotection by anti-inflammation, antioxidant, anti-apoptosis, and circulation improvement for myocardial I/R injury ([@B84]) was an innovative strategy for antagonizing the injurious biochemical and molecular events that eventually resulted in irreversible ischemic injury ([@B81]). The included preclinical trials presented the main active components of the most frequently used herbs that performed anti-inflammatory, anti-oxidation, anti-apoptosis, energy metabolism regulation, and circulation improvement mechanisms in multiple models of I/R injury through multiple signal pathways, including the PI3K/Akt signaling pathway, AMPK/Akt/PKC pathway, PI3K/Akt/mTOR pathway, mitochondrial-dependent apoptotic pathway, P38MAPK pathway, eNOS phosphorylation, and p-JNK-NF-kappaB-TRPC6 pathway. Further studies of CHM for CHD should explore the multi-drug, multi-target signal pathway using novel techniques such as network pharmacological approach.

Conclusion {#s4_4}
----------

The findings from present study indicate that CHMs are beneficial for CHD and are generally safe. In addition, CHM exerted cardioprotection for CHD, possibly altering multiple signal pathways through anti-inflammatory, anti-oxidation, anti-apoptosis, circulation improvement, and energy metabolism regulation mechanisms.
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